Cellino Biotech Appoints Chris Gibson to Board of Directors

Chris Gibson, Ph.D., Co-Founder & CEO, Recursion ● Photo Credit: Recursion

CAMBRIDGE, Mass., Oct. 24, 2024 (VSNewsNetwork.com) – Cellino Biotech, Inc., a biotechnology company focused on advancing autonomous biomanufacturing for personalized regenerative medicines has announced the appointment of Chris Gibson to its Board of Directors. Gibson, the Co-Founder and CEO of Recursion, brings extensive leadership experience in AI-driven drug discovery to Cellino's board.

Gibson expressed his enthusiasm for joining the board, stating, "Cellino’s proprietary technology stack, including optical bioprocessing, closed cassettes, and image-guided co-pilots, has the potential to transform healthcare and bring potentially curative therapies to millions of patients. I look forward to working alongside Nabiha, the Cellino team, and the Board to make cell and tissue replacement therapies accessible to all."

Nabiha Saklayen, CEO and Co-Founder of Cellino, highlighted Gibson’s experience, noting, "We are thrilled to welcome Chris to our board. As a seasoned founder and CEO, his hands-on experience and operational insights will be invaluable as we scale our team and vision for patient impact."

@VSNewsNetwork

@VSNewsNetwork

Gibson’s leadership at Recursion includes spearheading partnerships with Roche/Genentech, Bayer, and NVIDIA. He also founded the non-profit Recursion Foundation, supporting the next generation of biotechnology founders.

Cellino’s focus on autologous induced pluripotent stem cell-derived regenerative therapies offers promising solutions for a range of medical conditions, particularly for diverse and aging patient populations.

For more information, visit www.cellinobio.com.

Source: Cellino Biotech, Inc.